Oh oh, Ad Blocker gedecteerd!
Het lijkt erop dat je een Ad Blocker gebruikt op De Beleggersgids. Gelieve de Ad Blocker uit te schakelen en advertenties toe te laten op onze website. De Beleggersgids is afhankelijk van inkomsten uit advertenties om jou alle artikels gratis te brengen. Gun je ons geen inkomsten? Ga verder

UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatment and research, is proud to present pivotal, long-term data on Cimzia® (certolizumab pegol), romosozumab, early phase molecules bimekizumab and dapirolizumab pegol, and patient-friendly injection devices in development at the Annual European Congress of Rheumatology (EULAR 2016) in London, England (8th – 11th June 2016). These data presentations offer new insights on the potential to improve patient experience and treatment outcomes across several diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), systemic lupus erythematosus (SLE), and osteoporosis in post-menopausal women.

 

“The mission of UCB Immunology is to deliver value beyond expectations to our patients. We know that many people living with immunological diseases experience suboptimal response on existing therapies. This unmet need drives UCB’s patient-centric approach towards scientific research and improving the patient experience,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB, Immunology Patient Value Unit, UCB. “Cimzia® data at the Annual European Congress of Rheumatology (EULAR 2016) help to build increased understanding around the product’s long-term safety and efficacy profile, while our pipeline data demonstrate momentum in bringing innovative new products to patients.”

Data highlights will include four-year efficacy and safety data from both the RAPID-axSpA trial for the treatment of patients with axSpA, including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), and the RAPID-PsA trial for the treatment of patients with PsA. Period 2 data from the C-EARLY™ Phase 3 study will be presented, comparing different treatment strategies by continuing CIMZIA® at the standard dose or reducing the dose frequency versus withdrawal, in disease-modifying antirheumatic drug (DMARD)-naïve early RA patients who achieved sustained low disease activity after one year of treatment with certolizumab pegol combined with optimized methotrexate.

Data being presented from UCB’s pipeline include Phase 3 results from the STRUCTURE study of romosozumab for osteoporosis in post-menopausal women, Phase 1b results in PsA for bimekizumab (UCB4940), an investigational monoclonal antibody specifically designed to potently and selectively inhibit the biological function of both IL-17A and IL-17F cytokines, and Phase 1 results for dapirolizumab pegol (CDP7657), an anti-CD40L pegylated Fab fragment being evaluated for SLE.

424 lezers bereikt
De Beleggersgids Redactie

1. Like onze Facebook pagina
2. Volg ons op Twitter
3. Schrijf je in op onze nieuwsbrieven
4. Plaats een berichtje op ons forum

De Beleggersgids

Heldere en begrijpbare kennis, inzichten, inspiratie en nieuws over investeren in vastgoed, beleggingen, investeringen en geld.

Al 8.010 abonnees en groeiend

Top
×

De interessantste artikels wekelijks in je mailbox? Schrijf je in!

Ik ga akkoord met de voorwaarden
×

De interessantste artikels in je mailbox.

Ik ga akkoord met de voorwaarden